Determinants of erythrocyte omega-3 fatty acid content in response to fish oil supplementation: a dose-response randomized controlled trial.
Determinants of erythrocyte omega-3 fatty acid content in response to fish oil supplementation: a dose-response randomized controlled trial.
复制标题
DOI：
10.1161/jaha.113.000513
复制
发表时间：
2013-11-19
影响因子：
5.4
通讯作者：
Kris-Etherton PM
中科院分区：
文献类型：
--
作者：
Flock MR;Skulas-Ray AC;Harris WS;Etherton TD;Fleming JA;Kris-Etherton PM
组成omega-3指数(O3I)的红细胞膜二十碳五烯酸(EPA)和二十二碳六烯酸(DHA)的含量可以预测心血管疾病的死亡率。达到目标O3I所需的EPA+DHA的量以及O3I对EPA+DHA摄入量变化的反应的决定因素是不明确的。这项研究的目的是建立一个健康成年人对EPA+DHA补充的O3I反应的预测模型，特别是确定决定反应的因素。对115名健康男性和女性进行了一项随机、安慰剂对照、双盲、平行组研究。每日服用5种剂量(0,300,600,900,1800 mg)中的一种作为安慰剂或鱼油补充剂，≈为5个月。在基线和研究结束时测量O3I。在基线时，两组之间的临床特征没有显著差异。O_3I呈剂量依赖性增加(P<；0.0001)，仅二次甲氧基异丙基异丙肾上腺素的剂量就占了O_3I反应变异性的68%(P<；0.0001)。调整后的单位体重剂量(g/kg)占70%(线性，P<；0.0001)。改善治疗反应预测的其他因素是基线O3I、年龄、性别和体力活动。总而言之，这些因素解释了78%的反应变异性(P<；0.0001)。我们的发现验证了O3I作为EPA+DHA消费的生物标记物的有效性，并确定了可用于定制EPA+DHA建议以实现目标O3I的其他因素，特别是体重。
The erythrocyte membrane content of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which constitutes the omega‐3 index (O3I), predicts cardiovascular disease mortality. The amount of EPA+DHA needed to achieve a target O3I is poorly defined, as are the determinants of the O3I response to a change in EPA+DHA intake. The objective of this study was to develop a predictive model of the O3I response to EPA+DHA supplementation in healthy adults, specifically identifying factors that determine the response. A randomized, placebo‐controlled, double‐blind, parallel‐group study was conducted in 115 healthy men and women. One of 5 doses (0, 300, 600, 900, 1800 mg) of EPA+DHA was given daily as placebo or fish oil supplements for ≈5 months. The O3I was measured at baseline and at the end of the study. There were no significant differences in the clinical characteristics between the groups at baseline. The O3I increased in a dose‐dependent manner (P<0.0001), with the dose of EPA+DHA alone accounting for 68% (quadratic, P<0.0001) of the variability in the O3I response. Dose adjusted per unit body weight (g/kg) accounted for 70% (linear, P<0.0001). Additional factors that improved prediction of treatment response were baseline O3I, age, sex, and physical activity. Collectively, these explained 78% of the response variability (P<0.0001). Our findings validate the O3I as a biomarker of EPA+DHA consumption and identify additional factors, particularly body weight, that can be used to tailor EPA+DHA recommendations to achieve a target O3I.